A Phase II Study of PDC-1421 Capsule to Evaluate the Safety and Efficacy in Patients With Major Depressive Disorder

Completed · Phase 2 · Has a placebo group

Conditions studied: Major Depressive Disorder

In brief

The purpose of this study is to evaluate the safety and efficacy in patients with major depressive disorder.

Key facts

Study ID

NCT02395978

Run by

BioLite, Inc.

People needed

72

Starts

2015-04-10

Expected to finish

2019-03-18

Last updated by the study team

2021-07-22

Who can join

Age: 20 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Outpatients aged 20-65 years
• Subjects must be able to understand and willing to sign informed consent
• Female subjects of child-bearing potential must test negative to pregnancy and use appropriate birth control method from the beginning of study to the 15 days later after ending of study
• Met criteria for MDD without psychotic features as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Text Revision® (DSM-IV-TR) and confirmed by use of the Mini International Neuropsychiatric Interview (MINI).
• 17-item HAM-D (Hamilton Rating Scale for Depression) total score ≧20 and CGI (Clinical Global Impression) total score ≧4

You may not qualify if…

• Have a current or previous major psychiatric disorders which be defined to be per the DSM-IV-TR, including obsessive-compulsive disorder, posttraumatic stress disorder, bipolar I or II, manic or hypomanic episode, schizophrenia, major Axis II disorders which might compromise the study, and major depression with psychotic symptoms, mental retardation.
• Use of any treatment for MDD in the last 2 weeks before visit 1 (4 weeks for fluoxetine).
• Use of psychoactive drugs within the last 2 weeks before visit 1 other than that subjects had insomnia who need the treatment as determined by the Investigator.
• Subjects who were non-responsive to two or more courses of antidepressant medications given an adequate dosage for symptom treatment within four weeks, or by the judgment of the investigator considered to have treatment resistant depression (TRD), or a history of electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS) or psychosurgery within the last year.
• Have a history of any seizure disorder.
• Any clinically significant abnormal vital sign, ECG, laboratory values as determined by the investigator which might interfere with the study.
• Any organic disorder caused u medical related depression which cannot be under well-controlled such as clinically significant in neurological, gastrointestinal, renal, hepatic, cardiovascular, respiratory, metabolic, endocrine, hematological or other major disorders
• Have a high suicidal risk as measured by MINI.
• Have a history of substance abuse within the past 6 months or a positive urine drug screen for any substance of abuse at visit 1.
• Have a history of severe allergies to more than 1 class of medication or multiple adverse drug reactions.

Where it is running

• Stanford Depression Research Clinic — San Francisco, California, United States
• Taipei Veterans General Hospital — Taipei, Taiwan
• Tri-Service General Hospital, Neihu Main Facility — Taipei, Taiwan
• Wan Fang Hospital — Taipei, Taiwan
• Linkou Chang Gung Memorial Hospital — Taoyuan, Taiwan

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.